SHANGHAI, China and CAMBRIDGE, Mass., USA – August 8, 2026
RiboX Therapeutics Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for RXIM002, an investigational circular RNA-based in vivo CAR-T therapy being developed for autoimmune cytopenias. The regulatory milestone supports the initiation of the POPULUS-1 Phase 1 clinical trial, marking a significant advancement for circular RNA therapeutics and in vivo cell therapy. According to RiboX, RXIM002 is the first circular RNA-based in vivo CAR-T therapy to receive FDA IND clearance. The candidate uses a targeted lipid nanoparticle (tLNP) delivery system to deliver circular RNA encoding a CD19-targeting chimeric antigen receptor (CAR) directly to T cells inside the patient. The approach is designed to generate functional CAR-T cells within the body, potentially avoiding the complex manufacturing requirements associated with conventional ex vivo CAR-T therapies.
RXIM002 Targets Pathogenic B Cells In Vivo
RXIM002 is designed to deliver circRNA encoding an anti-CD19 CAR through a targeted LNP platform. Following administration, the technology is intended to enable T cells to express the CAR and generate functional CAR-T cells in vivo. These cells are designed to recognize and eliminate CD19-positive B cells, which play an important role in the production of pathogenic autoantibodies associated with several autoimmune diseases. By reducing disease-driving B cells, RiboX believes RXIM002 could potentially promote an immune reset and durable drug-free remission in patients with B-cell-mediated autoimmune conditions. The in vivo strategy could also address some of the logistical challenges associated with conventional CAR-T treatment, which generally requires collection of a patient’s cells, laboratory-based genetic modification, manufacturing, quality testing and reinfusion. RiboX said its approach is intended to provide an off-the-shelf therapeutic strategy, potentially simplifying treatment and expanding access to CAR-T technology for autoimmune disease patients.
POPULUS-1 Phase 1 Study Begins Clinical Evaluation
The FDA IND clearance supports the POPULUS-1 Phase 1 clinical study, which will evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias. The initial patient population will include individuals with immune thrombocytopenia (ITP), an autoimmune cytopenia characterized by abnormally low platelet levels and an increased risk of bruising and bleeding. According to RiboX, ITP is associated with abnormal B-cell activity and pathogenic autoantibodies. RXIM002 is being developed to produce transient in vivo CAR-T cell activity capable of depleting pathogenic B cells while potentially preserving broader immune function. Before the FDA submission, RXIM002 had also been evaluated in investigator-initiated trials in China involving patients with autoimmune diseases. RiboX said follow-up remains ongoing for treated patients, with some participants monitored for more than six months. The company included the available safety and early efficacy data from all treated patients in its FDA IND package. Based on the submitted dataset, the FDA permitted an accelerated dose-titration approach and allowed a subcutaneous formulation to be incorporated into clinical development, potentially supporting future outpatient administration.
RiboX Expands Circular RNA Therapy Platform
The RXIM002 milestone strengthens RiboX’s broader strategy of developing engineered circular RNA therapeutics and targeted LNP technologies. Circular RNA is being explored as an emerging RNA modality because its closed molecular structure can support durable expression while avoiding some limitations associated with conventional linear RNA approaches. RiboX has developed proprietary circRNA and tLNP platforms designed to provide durable expression, precision delivery and broad therapeutic applicability across multiple disease areas. With RXIM002 advancing into Phase 1, the company is now evaluating whether its circular RNA-based in vivo CAR-T strategy can translate into meaningful clinical benefits for patients with difficult-to-treat autoimmune disorders. The program also represents a potential shift in the development of cell therapies by seeking to generate therapeutic CAR-T cells directly inside the patient rather than manufacturing them externally. If clinical development demonstrates acceptable safety and meaningful biological activity, RXIM002 could provide an important proof of concept for circRNA-enabled in vivo CAR-T therapy and support the expansion of this platform into additional B-cell-driven autoimmune diseases.
Source: RiboX Therapeutics press release



